Evidence map›Paper›PMID 34829213›Full record

ArticleJournal of fungi (Basel, Switzerland)2021

The Use of Voriconazole as Primary Prophylaxis for Invasive Fungal Infections in Patients Undergoing Allogeneic Stem Cell Transplantation: A Single Center's Experience.

Ali Atoui, Nadine Omeirat, Omar Fakhreddine, Raquelle El Alam, Zeina Kanafani, Iman Abou Dalle, Ali Bazarbachi, Jean El-Cheikh, Souha S Kanj

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of fungi (Basel, Switzerland), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.3field-weighted citation impact, top 42% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 4 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 1 institution in 1 country.

Ali AtouiBone Marrow Transplantation Program, Department of Internal Medicine, American University of Beirut, Beirut P.O. Box 113-6044, Lebanon.
Nadine OmeiratDepartment of Internal Medicine, American University of Beirut, Beirut P.O. Box 113-6044, Lebanon.
Omar FakhreddineDepartment of Internal Medicine, American University of Beirut, Beirut P.O. Box 113-6044, Lebanon.
Raquelle El AlamDepartment of Diagnostic Radiology, American University of Beirut, Beirut P.O. Box 113-6044, Lebanon.ORCID 0000-0002-4296-6095
Zeina KanafaniInfectious Disease, Department of Internal Medicine, American University of Beirut, Beirut P.O. Box 113-6044, Lebanon.
Iman Abou DalleBone Marrow Transplantation Program, Department of Internal Medicine, American University of Beirut, Beirut P.O. Box 113-6044, Lebanon.
Ali BazarbachiBone Marrow Transplantation Program, Department of Internal Medicine, American University of Beirut, Beirut P.O. Box 113-6044, Lebanon.
Jean El-CheikhBone Marrow Transplantation Program, Department of Internal Medicine, American University of Beirut, Beirut P.O. Box 113-6044, Lebanon.
Souha S KanjInfectious Disease, Department of Internal Medicine, American University of Beirut, Beirut P.O. Box 113-6044, Lebanon.
American University of Beirut · LB

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundInvasive fungal infections (IFI) following allogeneic stem cell transplant (allo-HCT) are associated with high morbidity and mortality. Primary prophylaxis using voriconazole has been shown to decrease the incidence of IFI.

methodsWe conducted a retrospective analysis at the Bone Marrow Transplant (BMT) unit of the American University of Beirut including 195 patients who underwent allo-HCT for hematological malignancies and received voriconazole as primary prophylaxis for IFI. The primary endpoints were based on the incidence of IFI at day 100 and day 180, and the secondary endpoint based on fungal-free survival.

resultsFor the study, 195 patients who underwent allo-HCT between January 2015 and March 2021 were included. The median age at transplant was 43 years. Of the patients, 63% were male, and the majority of patients were diagnosed with acute myeloid leukemia (AML) (60%). Voriconazole was given for a median of 90 days and was interrupted in 20 patients. The majority of IFI cases were probable invasive aspergillosis (8%). The incidence of IFI including proven, probable and possible IFI was 34%. The incidence of proven and probable IFI was 5% were 8%, respectively. The incidence of proven-probable (PP-IFI) was 5.1% at day 100 and 6.6% at day 180. The majority of PP-IFI cases were invasive aspergillosis (8%). A univariate analysis of patients, transplant characteristics and IFI showed a significant correlation between the type of donor, disease status before transplant, graft-versus-host disease prophylaxis used and incidence of IFI. Only disease status post-transplant showed a significant correlation with fungal-free survival in the multivariate analysis.

conclusionPrimary prophylaxis with voriconazole in allo-HCT is associated with a low incidence of IFI. More studies are required to compare various antifungal agents in this setting.

Indexed as

allogeneic transplanthematological malignanciesinvasive fungal infectionprimary prophylaxisvoriconazole

Identifiers

PMID34829213
PMCPMC8622597
OpenAlexW3209957536

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.